Adage Capital Partners Gp, L.L.C. Jounce Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $17.5 Million - $23.7 Million	-2,456,023 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $141,120 - $244,440	28,000 Added 1.15%	2,456,023 $18.2 Million
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $6.43 Million - $13.3 Million	956,023 Added 64.95%	2,428,023 $24.9 Million
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $8.72 Million - $14.1 Million	1,368,624 Added 1323.93%	1,472,000 $10.3 Million
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $473,462 - $1.13 Million	103,376 New	103,376 $844,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.